Showing results (271-280 of 469) with videos related to
Sort By:
Pageof 47
Cancer Cytopathology|July 20, 2012
Interrater agreement of anal cytologyTeresa M Darragh, Diane Tokugawa, Philip E Castle, et al.The American Journal of Pathology|September 26, 2003
Detection of genomic amplification of the human telomerase gene (TERC) in cytologic specimens as a genetic test for the diagnosis of cervical dysplasiaKerstin Heselmeyer-Haddad, Viktor Janz, Philip E Castle, et al.Gynecologic Oncology Reports|July 9, 2020
A scoping review: Facilitators and barriers of cervical cancer screening and early diagnosis of breast cancer in Sub-Saharan African health settingsAmanda J Pierz, Thomas C Randall, Philip E Castle, et al.Journal of the National Cancer Institute|December 22, 2018
Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening ResultsPhilip E Castle, Walter K Kinney, Xiaonan Xue, et al.Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap resultsHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap resultsHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.Journal of Lower Genital Tract Disease|March 23, 2013
Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or lessHormuzd A Katki, Julia C Gage, Mark Schiffman, et al.Journal of Lower Genital Tract Disease|March 23, 2013
Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment managementHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 6, 2022
Randomized Implementation of a Primary Human Papillomavirus Testing-based Cervical Cancer Screening Protocol for Women 34 to 69 Years in NorwayMari Nygård, Birgit Engesæter, Philip E Castle, et al.Journal of Lower Genital Tract Disease|March 23, 2013
Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelinesHormuzd A Katki, Mark Schiffman, Philip E Castle, et al.Pageof 47